Cilazapril
Based on 1 publication(s) in Google Scholar
Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 88768-40-5
- Formel: C22H31N3O5
- Molecular Weight:417.50
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cilazapril
More
Biologische Aktivität
Cilazapril (0.1-0.3 mg/kg orally) dose-dependently reduces plasma ACE activity and the pressor response to angiotensin in cats[1].
Cilazapril (10 mg/kg orally twice daily for 3.5 days) gradually reduces blood pressure in dogs with volume-depleted renal hypertension.
Cilazapril (10 mg/kg; p.o.; 2 weeks) decreases blood pressure, reduces heart weight to body weight ratio, and improves postischemic myocardial function in hyperthyroid rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 88768-40-5
-
Molecular Weight 417.50
-
Formel C22H31N3O5
-
SMILES
O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O
-
Synonyms
Ro 31-2848
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
Verweise
[1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. [Content Brief]
[2]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15. [Content Brief]
[3]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39. [Content Brief]
[4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. [Content Brief]
[5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Cilazapril Related Classifications
HY-A0043 Related Classifications
Powered by Bioz